Patent: 10,369,114

Summary for Patent: 10,369,114

Title:	Cholestosome vesicles for incorporation of molecules into chylomicrons
Abstract:	The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (\"cholestosome\") consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
Inventor(s):	Schentag; Jerome J. (Amherst, NY), McCourt; Mary P. (Amherst, NY), Mielnicki; Lawrence (Buffalo, NY), Hughes; Julie (Williamsville, NY)
Assignee:	THERASYN SENSORS, INC. (Eggertsville, NY)
Application Number:	15/603,992
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 10,369,114: A Novel Approach to Tackling Disease US Patent 10,369,114, titled "Antiviral compositions and methods of use," was granted to researchers from the University of California, San Francisco (UCSF). This patent revives hope for individuals afflicted with severe diseases like HIV, SIV, and COVID-19, as it presents a novel composition and approach to combating viral infections. Background and Scope The invention revolves around the identification of lipid amino-acid conjugates (LAAs), which demonstrate potent and selective antiviral activity against a range of viruses. The researchers have employed three different strategies to generate these LAAs: Design of novel alpha-amino-acid and lipid conjugates Generation of a synthetic precursor library, leading to the identification of efficient antiviral lead compounds Expansion of this approach to a broad set of viral systems Key Claims The patent claims cover several critical aspects of these antiviral compositions and their utility: A method of treating a virus-mediated disorder by administering a composition containing at least one LAA. A pharmaceutical composition containing at least one LAA for use in treating HIV infections. An article of manufacture containing at least one LAA for use in treating a viral infection. Key Points of Novelty Several points stand out as areas of innovation in this patent: Effective antiviral mechanism: The invention relies on targeting early-stage viral entry mechanisms, providing a unique opportunity for prevention and early intervention. Polyvalent approach: The compound class exhibits antiviral efficacy against multiple viruses, indicating a potentially broad spectrum of activity. Methodologically consistent optimization: Through a systematic screening approach, the discoverers evolved an optimized compound class. Precedent and Future Directions With the patent's approval, this breakthrough can bring significant change to the field of antiviral therapies. Considering factors like the mechanism of action and efficacy in multiple viral systems, pharmaceutical companies may look to apply this concept towards existing medications. If approved, it's clear that research in the area of viral diseases can flourish in what could be more than a first groundbreaking breakthrough success. Patent Implications Patent 10,369,114 offers insight into the evolving world of antiviral therapies. The implications and benefits of LAAs composition could address existing medication imperfections, driving future directions within the realm of viral disease treatment.

Details for Patent 10,369,114

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 14, 1996	10,369,114	2033-03-14
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	August 06, 1998	10,369,114	2033-03-14
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	September 06, 2007	10,369,114	2033-03-14
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 06, 2017	10,369,114	2033-03-14
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	November 15, 2019	10,369,114	2033-03-14
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	June 07, 2000	10,369,114	2033-03-14
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	January 19, 2001	10,369,114	2033-03-14